Shares in NewAmsterdam Pharma were sliding today after it reported a phase 3 trial of obicetrapib that met its primary objective but didn't meet the expectations of some analysts and invest
NewAmsterdam Pharma's bold play to resurrect an all-but defunct cholesterol-lowering drug class has been rewarded with a positive phase 2 trial of its oral CETP inhibitor obicetrapib.
NewAmsterdam Pharma has charted out a route to a Nasdaq listing by merging with black cheque company Frazier Lifesciences in a deal that will provide additional cash for its main drug candi